Glycolysis plays a critical role in the onset, progression, and therapeutic response of ccRCC, suggesting that YBX1 may significantly influence ccRCC metabolic processes via glycolysis-related proteins (e.g., LDHA, PKM, ENO1). This evidence concerns the gene LDHA and nonpapillary renal cell carcinoma.